Myriad Genetics Company Profile (NASDAQ:MYGN)

About Myriad Genetics

Myriad Genetics logoMyriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing, or assess a patient's risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MYGN
  • CUSIP: 62855J10
Key Metrics:
  • Previous Close: $20.70
  • 50 Day Moving Average: $21.00
  • 200 Day Moving Average: $30.83
  • 52-Week Range: $19.10 - $46.24
  • Trailing P/E Ratio: 12.11
  • Foreward P/E Ratio: 16.83
  • P/E Growth: 3.67
  • Market Cap: $1.43B
  • Outstanding Shares: 69,134,000
  • Beta: 0.56
Profitability:
  • Net Margins: 14.98%
  • Return on Equity: 16.06%
  • Return on Assets: 14.03%
Debt:
  • Current Ratio: 4.35%
  • Quick Ratio: 3.82%
Additional Links:
Companies Related to Myriad Genetics:

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.07)
Consensus Price Target: $31.92 (54.22% upside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
Show:
DateFirmActionRatingPrice TargetDetails
8/21/2016Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details
8/11/2016Jefferies GroupLower Price TargetHold$34.00 -> $20.00View Rating Details
8/11/2016StephensSet Price TargetBuy$30.00View Rating Details
8/10/2016Morgan StanleyLower Price TargetUnderweight$25.00 -> $21.00View Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00View Rating Details
8/10/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$47.00 -> $22.00View Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00View Rating Details
8/10/2016Barclays PLCDowngradeOverweight -> Equal Weight$50.00 -> $24.00View Rating Details
7/29/2016Bank of America Corp.DowngradeNeutral -> Underperform$25.00View Rating Details
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00View Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00View Rating Details
3/23/2016Goldman Sachs Group Inc.Boost Price Target$40.00View Rating Details
2/3/2016Deutsche Bank AGReiterated RatingBuy$52.00 -> $51.00View Rating Details
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details
9/20/2015William BlairReiterated RatingBuyView Rating Details
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00View Rating Details
5/28/2015Credit Suisse Group AGReiterated RatingUnderperformView Rating Details
5/7/2015Cantor FitzgeraldReiterated RatingBuy$43.00View Rating Details
2/4/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Myriad Genetics (NASDAQ:MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.32$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.48$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
Current Year EPS Consensus Estimate: $1.06 EPS
Next Year EPS Consensus Estimate: $1.23 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.37$0.38$0.38
Q2 20164$0.41$0.43$0.42
Q3 20161$0.42$0.42$0.42
Q4 20162$0.36$0.45$0.41
Q1 20173$0.25$0.42$0.31
Q2 20173$0.29$0.46$0.35
Q3 20173$0.27$0.43$0.32
Q4 20173$0.25$0.38$0.29
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Myriad Genetics (NASDAQ:MYGN)
Insider Ownership Percentage: 5.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.00View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline
globenewswire.com logoMyriad Appoints Chip Parkinson as EVP for Reimbursement Strategy - GlobeNewswire (press release) (NASDAQ:MYGN)
globenewswire.com - September 29 at 6:17 PM
publicnow.com logoMyriad Appoints Chip Parkinson as EVP for Reimbursement Strategy (NASDAQ:MYGN)
www.publicnow.com - September 29 at 11:26 AM
fool.com logo3 Signs Invitae's Best Days Are Ahead (NASDAQ:MYGN)
www.fool.com - September 28 at 6:01 PM
seekingalpha.com logoExpert interview today on outlook for Myriad Genetics (NASDAQ:MYGN)
seekingalpha.com - September 27 at 12:30 PM
mysmartrend.com logoMyriad Genetics Shares Down 37.8% Since SmarTrend's Sell Call (MYGN) (NASDAQ:MYGN)
www.mysmartrend.com - September 27 at 10:53 AM
4-traders.com logoMyriad Genetics : to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing (NASDAQ:MYGN)
www.4-traders.com - September 26 at 11:01 AM
publicnow.com logoMyriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing (NASDAQ:MYGN)
www.publicnow.com - September 26 at 11:01 AM
News IconServices stocks for your portfolio: Myriad Genetics, Inc. (MYGN), The ... - The Independent Republic (NASDAQ:MYGN)
theindependentrepublic.com - September 22 at 6:00 PM
News IconAnalysts Valuations For Two Stocks: Myriad Genetics (NASDAQ:MYGN), Achillion Pharmaceuticals (NASDAQ:ACHN) - The Voice Registrar (NASDAQ:MYGN)
voiceregistrar.com - September 22 at 6:00 PM
nasdaq.com logoMyriad Genetics Becomes Oversold (MYGN) (NASDAQ:MYGN)
www.nasdaq.com - September 22 at 11:05 AM
capitalcube.com logoETF’s with exposure to Myriad Genetics, Inc. : September 21, 2016 (NASDAQ:MYGN)
www.capitalcube.com - September 21 at 5:57 PM
mysmartrend.com logoShares of MYGN Down 39.0% Since Downtrend Call on Shares (NASDAQ:MYGN)
www.mysmartrend.com - September 19 at 6:17 PM
News IconAnalysts Valuations For Two Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Myriad Genetics, Inc. (NASDAQ:MYGN) - The Voice Registrar (NASDAQ:MYGN)
voiceregistrar.com - September 17 at 5:54 PM
fool.com logoMyriad Genetics Shouldn't Overlook This Tiny Competitor (NASDAQ:MYGN)
www.fool.com - September 17 at 3:12 PM
capitalcube.com logoETF’s with exposure to Myriad Genetics, Inc. : September 9, 2016 (NASDAQ:MYGN)
www.capitalcube.com - September 9 at 6:00 PM
streetinsider.com logoMyriad Genetics (MYGN) Announces Presentation of Positive TruCulture Incubation Data by Institut Pasteur (NASDAQ:MYGN)
www.streetinsider.com - September 9 at 11:01 AM
News IconStock Slipping Down Over the Past Five Trading Sessions: Myriad Genetics, Inc. (NASDAQ:MYGN) (NASDAQ:MYGN)
www.nationaldailypress.com - September 9 at 11:01 AM
istreetwire.com logoEquities Trend Analysis: Myriad Genetics, Inc. (MYGN), Tailored Brands, Inc. (TLRD), Weyerhaeuser Co. (WY) - iStreetWire (NASDAQ:MYGN)
istreetwire.com - September 8 at 10:08 AM
News IconAnalysts Valuations For Two Stocks: Myriad Genetics, Inc. (NASDAQ:MYGN), Bed Bath & Beyond Inc. (NASDAQ:BBBY) - The Voice Registrar (NASDAQ:MYGN)
voiceregistrar.com - September 7 at 6:29 PM
fool.com logoHere's Why Myriad Genetics, Inc. Had Its DNA Scrambled, Causing Its Stock to Fall 34% in August (NASDAQ:MYGN)
www.fool.com - September 7 at 2:52 PM
streetinsider.com logoMyriad Genetics (MYGN) Announces Presentation of Positive TruCulture Incubation Data by Institut Pasteur - StreetInsider.com (NASDAQ:MYGN)
www.streetinsider.com - September 7 at 9:51 AM
nasdaq.com logoMyriad Genetics Adds Assurex Health, Grows in Neuroscience - Nasdaq (NASDAQ:MYGN)
www.nasdaq.com - September 7 at 9:51 AM
finance.yahoo.com logoMyriad RBM’s TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur (NASDAQ:MYGN)
finance.yahoo.com - September 7 at 9:51 AM
publicnow.com logoMyriad RBM's TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur (NASDAQ:MYGN)
www.publicnow.com - September 7 at 9:51 AM
News IconStock Struggling for the Quarter: Myriad Genetics, Inc. (NASDAQ:MYGN) - Post News (NASDAQ:MYGN)
www.kentuckypostnews.com - September 3 at 5:40 PM
globenewswire.com logoMyriad Genetics Completes Acquisition of Assurex Health - GlobeNewswire (press release) (NASDAQ:MYGN)
www.globenewswire.com - September 2 at 11:09 AM
News IconAnalysts Valuations For Two Stocks: Myriad Genetics, Inc. (NASDAQ:MYGN), Olin Corporation (NYSE:OLN) - The Voice Registrar (NASDAQ:MYGN)
voiceregistrar.com - September 2 at 11:09 AM
publicnow.com logoMyriad Genetics Completes Acquisition of Assurex Health (NASDAQ:MYGN)
www.publicnow.com - September 1 at 6:16 PM
biz.yahoo.com logoMYRIAD GENETICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct Fina (NASDAQ:MYGN)
biz.yahoo.com - September 1 at 6:16 PM
feeds.reuters.com logoBRIEF-Myriad Genetics to enter into a credit agreement (NASDAQ:MYGN)
feeds.reuters.com - September 1 at 4:57 PM
News IconShares Slipping Lower Over the Past Month: Myriad Genetics, Inc. (NASDAQ:MYGN) - Post News (NASDAQ:MYGN)
www.kentuckypostnews.com - September 1 at 9:29 AM
News IconThe Key Numbers To Watch From Myriad Genetics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MYGN)
voiceregistrar.com - September 1 at 9:29 AM
finance.yahoo.com logoMyriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference (NASDAQ:MYGN)
finance.yahoo.com - August 30 at 6:20 PM
bizjournals.com logoAssurex Health CEO Gina Drosos to speak at Bizwomen Breakfast (NASDAQ:MYGN)
www.bizjournals.com - August 30 at 9:39 AM
capitalcube.com logoETF’s with exposure to Myriad Genetics, Inc. : August 29, 2016 (NASDAQ:MYGN)
www.capitalcube.com - August 29 at 6:09 PM
mysmartrend.com logoShares of MYGN Down 39.7% Since Downtrend Call on Shares (NASDAQ:MYGN)
www.mysmartrend.com - August 25 at 6:19 PM
istreetwire.com logoStocks in Focus: Myriad Genetics, Inc. (MYGN), Facebook, Inc. (FB), Colony Capital, Inc. (CLNY) - iStreetWire (NASDAQ:MYGN)
istreetwire.com - August 25 at 11:27 AM
capitalcube.com logoMyriad Genetics, Inc. :MYGN-US: Earnings Analysis: 2016 By the Numbers : August 23, 2016 (NASDAQ:MYGN)
www.capitalcube.com - August 23 at 10:46 AM
finance.yahoo.com logoMYRIAD GENETICS INC Financials (NASDAQ:MYGN)
finance.yahoo.com - August 20 at 6:04 PM
marketnewsvideo.com logoMYGN: Insiders vs. Shorts (NASDAQ:MYGN)
www.marketnewsvideo.com - August 19 at 6:16 PM
mysmartrend.com logoMyriad Genetics Has Returned 39.6% Since SmarTrend Recommendation (MYGN) (NASDAQ:MYGN)
www.mysmartrend.com - August 19 at 9:24 AM
finance.yahoo.com logoWeakness Seen in Myriad Genetics (MYGN) Estimates: Should You Stay Away? (NASDAQ:MYGN)
finance.yahoo.com - August 19 at 9:24 AM
News IconIt's Earnings Time: What to Do with Myriad Genetics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MYGN)
voiceregistrar.com - August 18 at 6:29 PM
investornewswire.com logoAnalysts See Sales Of $1009.5 For Myriad Genetics, Inc. (NASDAQ:MYGN) - Investor Newswire (NASDAQ:MYGN)
www.investornewswire.com - August 18 at 9:25 AM
bizjournals.com logoEXCLUSIVE: Assurex Health buyer has a Cincinnati connection (NASDAQ:MYGN)
www.bizjournals.com - August 16 at 6:31 PM
istreetwire.com logoTrader Alert: Zoetis Inc. (ZTS), CenturyLink, Inc. (CTL), Myriad Genetics, Inc. (MYGN) - iStreetWire (NASDAQ:MYGN)
istreetwire.com - August 16 at 9:39 AM
capitalcube.com logoETF’s with exposure to Myriad Genetics, Inc. : August 15, 2016 (NASDAQ:MYGN)
www.capitalcube.com - August 15 at 6:33 PM
capitalcube.com logoMyriad Genetics, Inc. :MYGN-US: Earnings Analysis: Q4, 2016 By the Numbers : August 12, 2016 (NASDAQ:MYGN)
www.capitalcube.com - August 12 at 6:26 PM
nasdaq.com logoMyriad Genetics Inc. (MYGN) Has Plunged To A New Low After Weak Q4 Report (NASDAQ:MYGN)
www.nasdaq.com - August 12 at 9:35 AM
finance.yahoo.com logoMyriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session (NASDAQ:MYGN)
finance.yahoo.com - August 12 at 9:35 AM

Social

Myriad Genetics (NASDAQ:MYGN) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff